Status:
TERMINATED
Metabolomic Profiling of Novel Mediators of Vascular Function
Lead Sponsor:
Brigham and Women's Hospital
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to identify and characterize specific chemicals and metabolic pathways that change with forearm ischemia. These changes will be compared with forearm blood flow and flow-m...
Eligibility Criteria
Inclusion
- Adults age 18 or older
- Type 2 diabetes mellitus
Exclusion
- Type 1 diabetes mellitus
- Type 2 diabetics taking insulin, thiazolidinediones (rosiglitazone or pioglitazone), an amylin analog (Symlin \[pramlintide\]), or incretin mimetics (Byetta \[exenatide\])
- Pregnancy
- Uncontrolled hypertension, \> 180/100 mmHg
Key Trial Info
Start Date :
May 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2018
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00762242
Start Date
May 1 2007
End Date
February 1 2018
Last Update
December 12 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115